國立虎尾科技大學 |

BRAF Targets in Melanoma = Biological Mechanisms, Resistance, and Drug Discovery /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	BRAF Targets in Melanoma/ edited by Ryan J. Sullivan.
Reminder of title:	Biological Mechanisms, Resistance, and Drug Discovery /
other author:	Sullivan, Ryan J.
Description:	VIII, 204 p. 26 illus., 21 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Cancer research. -
Online resource:	https://doi.org/10.1007/978-1-4939-2143-0
ISBN:	9781493921430

BRAF Targets in Melanoma = Biological Mechanisms, Resistance, and Drug Discovery /
BRAF Targets in MelanomaBiological Mechanisms, Resistance, and Drug Discovery /[electronic resource] :edited by Ryan J. Sullivan. - 1st ed. 2015. - VIII, 204 p. 26 illus., 21 illus. in color.online resource. - Cancer Drug Discovery and Development,822196-9906 ;. - Cancer Drug Discovery and Development,.

Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better.

This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.

ISBN: 9781493921430

Standard No.: 10.1007/978-1-4939-2143-0doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

BRAF Targets in Melanoma = Biological Mechanisms, Resistance, and Drug Discovery /
LDR:03233nam a22004095i 4500 001 966415
003 DE-He213
005 20200703162709.0
007 cr nn 008mamaa
008 201211s2015 xxu| s |||| 0|eng d
020 $a 9781493921430 $9 978-1-4939-2143-0
024 7 $a 10.1007/978-1-4939-2143-0 $2 doi
035 $a 978-1-4939-2143-0
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a BRAF Targets in Melanoma $h [electronic resource] : $b Biological Mechanisms, Resistance, and Drug Discovery / $c edited by Ryan J. Sullivan.
250 $a 1st ed. 2015.
264 1 $a New York, NY : $b Springer New York : $b Imprint: Humana, $c 2015.
300 $a VIII, 204 p. 26 illus., 21 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Cancer Drug Discovery and Development, $x 2196-9906 ; $v 82
505 0 $a Melanoma: Historical Context -- Melanoma Pathogenesis -- Molecular Diagnostics and Tumor Mutational Analysis -- Clinical Utility of BRAF-targeted therapy in Melanoma -- The Ethics of Randomized Trials in Oncology -- Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma -- Targeting the cell cycle and p53 in combination with BRAF-directed therapy -- Combination BRAF-directed therapy and immunotherapy -- Moving Forward: Making BRAF-Targeted Therapy Better.
520 $a This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.
650 0 $a Cancer research. $3 1253664
650 0 $a Molecular biology. $3 583443
650 0 $a Medical microbiology. $3 583124
650 0 $a Pharmacology. $3 583819
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Molecular Medicine. $3 668353
650 2 4 $a Medical Microbiology. $3 668401
650 2 4 $a Pharmacology/Toxicology. $3 593882
700 1 $a Sullivan, Ryan J. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1063740
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9781493921447
776 0 8 $i Printed edition: $z 9781493921423
776 0 8 $i Printed edition: $z 9781493953486
830 0 $a Cancer Drug Discovery and Development, $x 2196-9906 $3 1253870
856 4 0 $u https://doi.org/10.1007/978-1-4939-2143-0
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)